MX2021012903A - Moduladores de la via de respuesta integrada al estres. - Google Patents

Moduladores de la via de respuesta integrada al estres.

Info

Publication number
MX2021012903A
MX2021012903A MX2021012903A MX2021012903A MX2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A MX 2021012903 A MX2021012903 A MX 2021012903A
Authority
MX
Mexico
Prior art keywords
sup
stress response
modulators
integrated stress
response pathway
Prior art date
Application number
MX2021012903A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Francis Palmer
Christopher John Brown
Daryl Simon Walter
Holly Atton
James Lindsay Carr
Serge Convers-Reignier
Michael Corr
Marissa Flower
Mohamad Sabbah
Scott Sadler
Jonathan Shine
Irena Doly Reboule
Original Assignee
Evotec Int Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec Int Gmbh filed Critical Evotec Int Gmbh
Publication of MX2021012903A publication Critical patent/MX2021012903A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of El Displays (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Semiconductor Integrated Circuits (AREA)
MX2021012903A 2019-04-23 2020-04-22 Moduladores de la via de respuesta integrada al estres. MX2021012903A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19170504 2019-04-23
EP19216875 2019-12-17
PCT/EP2020/061150 WO2020216766A1 (en) 2019-04-23 2020-04-22 Modulators of the integrated stress response pathway

Publications (1)

Publication Number Publication Date
MX2021012903A true MX2021012903A (es) 2022-01-18

Family

ID=70289816

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021012903A MX2021012903A (es) 2019-04-23 2020-04-22 Moduladores de la via de respuesta integrada al estres.
MX2024015479A MX2024015479A (es) 2019-04-23 2021-10-21 Moduladores de la via de respuesta integrada al estres

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024015479A MX2024015479A (es) 2019-04-23 2021-10-21 Moduladores de la via de respuesta integrada al estres

Country Status (15)

Country Link
US (2) US12258338B2 (cg-RX-API-DMAC7.html)
EP (1) EP3959198A1 (cg-RX-API-DMAC7.html)
JP (2) JP7590343B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004105A (cg-RX-API-DMAC7.html)
CN (1) CN113993850B (cg-RX-API-DMAC7.html)
AU (2) AU2020261234B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021020402A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002772A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021014292A2 (cg-RX-API-DMAC7.html)
IL (1) IL287379B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021012903A (cg-RX-API-DMAC7.html)
PE (1) PE20220961A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111119PA (cg-RX-API-DMAC7.html)
WO (1) WO2020216766A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202108151B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
US11166942B2 (en) 2018-06-05 2021-11-09 Praxis Biotech LLC Inhibitors of integrated stress response pathway
EP3924341A4 (en) 2019-02-13 2022-11-02 Denali Therapeutics Inc. Compounds, compositions and methods
CR20210426A (es) * 2019-02-13 2021-09-30 Denali Therapeutics Inc Compuestos, composiciones y métodos
MX2021012904A (es) * 2019-04-23 2022-01-18 Evotec Int Gmbh Moduladores de la via de respuesta al estres integrada.
JP2022536663A (ja) 2019-06-12 2022-08-18 プラクシス バイオテック エルエルシー 統合的ストレス応答経路のモジュレーター
WO2021165927A1 (en) * 2020-02-21 2021-08-26 Wockhardt Bio Ag 2-cyanopyrroldines, -piperidines or -dazepines as hyperglycemic agents
KR20220151635A (ko) 2020-03-11 2022-11-15 에보텍 인터내셔널 게엠베하 통합 스트레스 반응 경로의 조절제
MX2023004677A (es) * 2020-10-22 2023-05-24 Evotec Int Gmbh Moduladores de la via de respuesta integrada al estres.
ES2997335T3 (en) 2020-10-22 2025-02-17 Evotec Int Gmbh Modulators of the integrated stress response pathway
CA3195290A1 (en) 2020-10-22 2022-04-28 Holly Victoria Atton Modulators of the integrated stress response pathway
TW202241857A (zh) 2020-12-18 2022-11-01 美商戴納立製藥公司 化合物之固體形式
WO2022212902A1 (en) * 2021-04-02 2022-10-06 Altos Labs, Inc. Modulators of integrated stress response pathway
AU2023384649A1 (en) 2022-11-21 2025-05-22 Shenzhen Zhongge Biological Technology Co., Ltd. Compound, pharmaceutical composition containing same, synthesis method therefor and use thereof
CN116854623B (zh) * 2023-07-11 2025-08-05 齐鲁安替制药有限公司 一种阿维巴坦中间体的制备方法
CN121986087A (zh) 2023-10-13 2026-05-05 国立研究开发法人国立精神·神经医疗研究中心 神经保护剂
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639761B1 (en) 1999-12-02 2003-10-28 Seagate Technology Llc Micro-actuator damping and humidity protection
AU2001233044A1 (en) * 2000-01-28 2001-08-07 Akkadix Corporation Methods for killing nematodes and nematode eggs using bis-amino-1,2,4-thiadiazoles
US7915433B2 (en) 2004-04-16 2011-03-29 Wayne State University Tri-substituted 2-benzhydryl 5-benzlamino-tetrahydro-pyran-4-OL and 6-benzhydryl-4-benzylamino-tetrahydro-pyran-3-OL analogues, and novel 3,6 disubstituted pyran derivatives
WO2014144952A2 (en) * 2013-03-15 2014-09-18 Peter Walter Modulators of the eif2alpha pathway
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
WO2017046739A1 (en) 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
TW201808888A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808914A (zh) * 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TW201808903A (zh) 2016-05-05 2018-03-16 嘉來克生命科學有限責任公司 整合應激途徑之調節劑
TWI920577B (zh) 2016-05-05 2026-04-01 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
CA3026983A1 (en) * 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
RU2018145734A (ru) * 2016-06-08 2020-07-14 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Химические соединения в качестве ингибиторов atf4 пути
CN110730777A (zh) 2017-06-07 2020-01-24 葛兰素史密斯克莱知识产权发展有限公司 作为atf4通路抑制剂的化学化合物
EP3649108A1 (en) 2017-07-03 2020-05-13 GlaxoSmithKline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
WO2019008506A1 (en) 2017-07-03 2019-01-10 Glaxosmithkline Intellectual Property Development Limited N- (3- (2- (4-CHLOROPHENOXY) ACETAMIDO) BICYCLO [1.1.1] PENTAN-1-YL) -2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
DE102017213834A1 (de) * 2017-08-08 2019-02-14 Robert Bosch Gmbh Sende-/Empfangseinrichtung für ein Bussystem und Verfahren zur Reduzierung einer Schwingneigung beim Übergang zwischen unterschiedlichen Bitzuständen
IL301709B2 (en) 2017-08-09 2025-07-01 Denali Therapeutics Inc Compounds, compositions and methods
TW201920129A (zh) 2017-09-01 2019-06-01 美商戴納立製藥公司 化合物、組合物及方法
BR112020008825A2 (pt) 2017-11-02 2020-10-20 Calico Life Sciences Llc moduladores da via de estresse integrada
MX2020004537A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía integrada del estrés.
JP2021501785A (ja) 2017-11-02 2021-01-21 カリコ ライフ サイエンシーズ エルエルシー 統合的ストレス経路の調節剤
EP3704125B1 (en) 2017-11-02 2026-03-11 Calico Life Sciences LLC Modulators of the integrated stress pathway
MX2020004538A (es) 2017-11-02 2020-09-18 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
UY37958A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
UY37956A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
SG11202004009TA (en) 2017-11-02 2020-05-28 Calico Life Sciences Llc Modulators of the integrated stress pathway
UY37957A (es) 2017-11-02 2019-05-31 Abbvie Inc Moduladores de la vía de estrés integrada
JP2021508336A (ja) 2017-12-13 2021-03-04 プラクシス バイオテック エルエルシー 統合的ストレス応答経路の阻害剤
WO2019183589A1 (en) 2018-03-23 2019-09-26 Denali Therapeutics Inc. Modulators of eukaryotic initiation factor 2
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors

Also Published As

Publication number Publication date
JP2022530049A (ja) 2022-06-27
PE20220961A1 (es) 2022-06-10
AU2026203062A1 (en) 2026-05-07
WO2020216766A1 (en) 2020-10-29
SG11202111119PA (en) 2021-11-29
JP2025024086A (ja) 2025-02-19
IL287379B1 (en) 2025-07-01
US20220227747A1 (en) 2022-07-21
IL287379B2 (en) 2025-11-01
US12258338B2 (en) 2025-03-25
JP7878648B2 (ja) 2026-06-23
CA3137213A1 (en) 2020-10-29
BR112021020402A2 (pt) 2021-12-07
US20250188071A1 (en) 2025-06-12
CO2021014292A2 (es) 2022-04-29
CN113993850A (zh) 2022-01-28
IL287379A (en) 2021-12-01
AU2020261234A1 (en) 2021-11-11
MX2024015479A (es) 2025-02-10
ZA202108151B (en) 2026-04-29
EP3959198A1 (en) 2022-03-02
AU2020261234B2 (en) 2026-02-05
KR20220004105A (ko) 2022-01-11
CL2021002772A1 (es) 2022-07-29
JP7590343B2 (ja) 2024-11-26
CN113993850B (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
MX2024015479A (es) Moduladores de la via de respuesta integrada al estres
MX2022009243A (es) Moduladores de la via de respuesta integrada al estres.
PH12020551578A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
PH12022550980A1 (en) Small molecule degraders of helios and methods of use
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MY204171A (en) Novel sulfonamide carboxamide compounds
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
CR20230143A (es) Degradadores de moléculas pequeñas de piperidinilo de helios y procedimientos de uso
EP4360707A3 (en) Compositions for treating spinal muscular atrophy
EP4252848A3 (en) Oxysterols and methods of use thereof
MX2020006459A (es) Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2021004940A (es) Derivados de piridinil sulfonamida, composiciones farmaceuticas y usos de estos.
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
MX2022011143A (es) Moduladores de la via de respuesta integrada al estres.
PH12021550258A1 (en) Cdk8/19 inhibitors
GEP20237459B (en) Thiadiazine derivatives
GEAP202215592A (en) Pharmaceutical composition comprising antiplatelet agent and gastric acid secretion inhibitor
MX2021003508A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
MX2021006095A (es) Pirazoles como moduladores de hemoglobina.
CR20230218A (es) Nuevos derivados de indazol acetileno
MX2023009285A (es) Compuestos novedosos.
MX2023004626A (es) Moduladores de la via de respuesta integrada al estres.